StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Clinical TrialNov 17, 2026, 05:35 PM

Inhibrx: Ozekibart Combo Shows 62.7% ORR in Ewing Sarcoma Trial

AI Summary

Inhibrx Biosciences, Inc. announced updated clinical data from its Phase 1/2 expansion study of ozekibart (INBRX-109) in combination with irinotecan and temozolomide for relapsed or refractory Ewing sarcoma. The data, to be presented at the Connective Tissue Oncology Society 2026 Annual Meeting, showed a 62.7% overall response rate (ORR) and an 86.3% disease control rate (DCR) in 51 response-evaluable patients. The company plans to advance ozekibart development based on these compelling results.

Key Highlights

  • Ozekibart combination achieved 62.7% ORR in relapsed/refractory Ewing sarcoma patients.
  • Disease Control Rate (DCR) reached 86.3% with durable responses observed.
  • Among 51 response-evaluable patients, 32.7% had complete or partial responses.
  • Median Progression Free Survival (mPFS) was 6.0 months.
  • Data shows meaningful improvement over historical benchmarks for irinotecan and temozolomide alone.
  • The combination demonstrated an acceptable and manageable safety profile.
  • The FDA has accepted the biologics license application for ozekibart in conventional chondrosarcoma.